Is factor investing still working?

Stock market exchange on the computer screen.

A large number of long-only multi-factor strategie
Continue Reading

Access the full content on Top1000funds.com

Join the global institutional investment platform read by the world's largest asset owners, fund managers and consultants.

New here

Create an account

Complimentary to register. We'll verify your details and grant access to the archive, our newsletters and the Asset Owner Directory (enhanced features coming soon).
Create your Top1000funds.com subscription account
Already a member

Sign in

Already activated your account? Sign in to continue reading and access your saved articles, preferences and member-only content.

2 responses to “Is factor investing still working?”

  1. ceo@scientificbeta.com

    Dear anonymous commentator,

    Your message unfortunately illustrates our introductory point on the lack of attention of many commentators to investment matters and the wrong conclusions drawn from partial or one-sided observations.

    Before replying to you on the substance, I would like to reply on the form of your conclusion. Contrary to what you have stated, the point of our article is not to present reality from the angle that suits us, but to return to that reality. If we did not make explicit reference to our multi-factor indices to speak about factor performance, it is simply because we think that contributions to a website such as Top 1000 Funds that is a reference for investors should remain essentially, if not scientific, then at least neutral from a commercial point of view. The research article that served as a reference for our contribution analyses the conditional performances of factors that are commonly defined in the academic literature and the construction method advocated for building long-only proxies for these multi-factors is also fairly common. We chose to communicate on these proxies to illustrate a simple point, which was that it was the conditionality of the factors, and not so much the factors themselves, that was the cause of performance that we qualified as disappointing over the last three years.

    As you have been able to observe, since you refer to a document published on our website and distributed widely to the press, we always communicate in a detailed manner on the performance of our indices and we have nothing to hide. Accusing us of lacking transparency while referring to one of our published documents to do so is, to say the least, fairly inconsistent in terms of the form.

    On the substance, since our article relates to the poor performance of factor strategies over three years, we would have liked there to have been at least a reference to what we wrote, and if there were comparisons to be made, perhaps use this same three-year period.

    As you know, measurement of returns is unfortunately highly sample-dependent and choosing very short periods of six months only amplifies the phenomenon. This poor statistical representation should at least lead commentators to avoid drawing overly hasty and definitive conclusions on performance observed over short periods, especially when the justification for the usefulness of the strategies involved is that they collect factor premia, which are long-term premia.

    As far as the USD48bn (as of June 30) invested in our indices is concerned, it is essentially in multi-factor indices. As we show in the abovementioned study, this factor diversification provided positive average performance over three years for the six factors in which our long-only multi-factor indices are invested. Nonetheless, and we think it is an advantage of our construction method compared to many other competing methods that do not allow this risk to be controlled, we observe a strong difference in performance over the last three years between our multi-factor indices that benefit from market-beta neutrality in long-only (market beta 1) and those that do not benefit from it. Scientific Beta offers this fiduciary choice to investors who can thereby choose the market conditionality of their factor investment strategies. De facto, in the context of a strong bull market and in our clients’ main investment regions (US, Developed ex-US and Eurozone), the Scientific Beta indices that benefit from the market beta adjustment (CAPM Beta 1) have performed positively compared to the cap-weighted index over the past three years.

    Moreover, since you seem to be concerned about our indices’ investability conditions, the same document to which you refer provides the live performance of our indices in the main investment regions (Table 2a, page 6) and it is easy to observe therefore that in real investment conditions, whatever the variants of our indices and the risk options chosen, these indices have also largely outperformed the reference cap-weighted indices. Like you, we like facts, but it is necessary to refer to them when one wants to speak of “real investment” in our indices.

    Finally, concerning the Sharpe ratio, we do not believe that Sharpe ratio objectives of 1 or greater than 1 are realistic in the long-only space. What we know is that over the long-term, as expressed in the document to which you refer (Table 2c, page 9), the Sharpe ratio of our multi-factor strategies has been 57% greater than that of the reference cap-weighted indices.

    Noël Amenc, CEO, Scientific Beta

  2. primail@ozemail.com.au

    The most ‘remotely serious investigation’ for investors – and the only one of any relevance – is how do the real investments deliver in terms of returns and risks.

    A simple look at the performance tables for Scientific Beta’s indexes (on which USD 43 Billion of assets are replicated – i.e. managed) is illuminating.

    Scientific Beta’s Smart Beta Index Performance Report to June 2019 can be found at:

    https://ml-eu.globenewswire.com/Resource/Download/4701aef5-043b-42fa-b33e-9b1fb8d27191

    In short, every single strategy (Index) in every single market, underperformed the Cap Weighted indexes in the year to June 2019.

    Every strategy also has Sharpe ratios over longer periods of less than 1, which suggests that they are not a particularly effective use of the risk budget.

    The question is not whether Factors / Smart Beta’s / Risk Premia / etc., delivers returns – yes of course they do

    The question is whether they deliver them in a manner useful for investors, and consistent with the way that they have been included into portfolios (i.e. sold to Trustees).

    The simple reality is that Risk Premia strategies do not meet that ‘investability threshold’ in general, and in recent years have failed to delivered the easily and consistently available return premia that was sold as being just lying around waiting to be ‘harvested’ by all these ‘smart’ strategies.

    In reality markets do not give away free lunches, and the purveyors of the fallacy that they do need to adjust to that reality, rather than trying to bend reality to fit with their preferences.

    John

Leave a Comment

Texas ERS reallocates to managers to help navigate concentrated equity market

Texas ERS reallocates to managers to help navigate concentrated equity market

Texas ERS' CIO David Veal says the fund is re-allocating around a quarter of its public equity portfolio to external managers, away from the internal team. ERS plans to upsize with existing fundamental mandates but also allocate to new incremental relationships with diversifying strategies.

Sort content by

AP4: Why a dynamic, shorter term allocation is paying off

Volatile markets have provided a rich hunting ground and opportunistic best ideas have come thick and fast for AP4’s new five-pronged global allocation made up of systematic equity, currency and rates, asset allocation, hedge funds/external mandates and analysis. Magdalena Högberg explains the risks and opportunities of the best ideas allocation.

New study flags risk in Dutch pensions’ concentrated stock strategy

Under strict ESG guidelines and pressure to closely engage with their investee companies, Dutch pension funds have developed an affinity for concentrated equity allocations with some owning as few as 65 stocks in their entire portfolio. But the Erasmus University flagged the diversification risk and higher volatility the strategy introduces.

GIC ups US equities allocation despite valuation worries

Singapore's GIC boosted its US equities allocation in the year to March 2025 despite the expectation that high valuations could "provide a challenging backdrop for forward returns”, according to the fund's latest annual report released on Friday. 

Rebalancing at UTIMCO: Why investors should worry about corporate earnings

In a recent board meeting, University of Texas Investment Management Co's head Rich Hall explained why he is concerned about corporate earnings' impact on equity returns. He also warned that as consumer and company spending slows, a recession can become self-fulfilling until new facts emerge to break the pattern.

Sweden’s FTN scouts for domestic, European small cap managers

Nordic pension giant the Swedish Fund Selection Agency (FTN) is on the hunt for active Swedish and European small cap equity managers in a SEK 46 billion ($4.6 billion) tender. It comes as asset owners revisit small cap strategies as a useful diversification from US mega cap equities.

NBIM seeks long/short, market-neutral strategies amid volatility

Norway's NBIM is looking to allocate several mandates to single-country and regional long/short equity strategies in Australia, Japan, Europe, and the US. Top1000funds.com examines the growing investor interest in these strategies as market volatility and stock dispersion create fresh opportunities for active managers.